Lipid-lowering for prevention of coronary heart disease: What policy now?

Clinical Science

Volumn 91, Issue 4, 1996, Pages 399-413

  Ul Haq, Iftikhar ^c   Ramsay, Lawrence E ^c   Pickin, David M ^a   Yeo, Wilfred W ^c   Jackson, Peter R ^c   Payne, John N ^b  

^a Medical Care Research Unit   (United Kingdom)

^b Sheffield Health   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Angina; Cholesterol; Coronary heart disease; Coronary risk; Lipids; Myocardial infarction; Primary prevention; Secondary prevention; Stroke

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE POLICY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; UNITED KINGDOM;

EID: 0029835717     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0910399     Document Type: Article

References (42)

1. Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. Br Med J 1993; 306: 1367-73.
2. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995; 91: 2274-82.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. Hulley SB, Walsh JMB, Newman TB. Health policy on blood cholesterol: time to change directions. Circulation 1992; 86: 1026-9.
5. Shepherd J, Cobbe SM, Ford I, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 133: 1301-7.
6. Keech A, Collins R, MacMahon S, et al for the Oxford Cholesterol Study Group. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-69.
7. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidaemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-31.
8. Oliver M, Poole-Wilson P, Shepherd J, Tikkanen MJ. Lower patients' cholesterol now. Br Med J 1995; 310: 1280-1.
9. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346: 1467-71.
10. Oliver MF. Statins prevent coronary heart disease. Lancet 1995; 344: 1378-9.
11. Pederson TR, Kjekshus J, Berg K, et al for the Scandinavian Simvastatin Survival Study Group. Cholesterol lowering and the utilisation of healthcare resources: results of the Scandinavian Simvastatin Survival Study (4S). Circulation (In press).
12. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31.
13. Anonymous. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel II). Circulation 1994; 89: 1333-445.
14. Jackson R, Beaglehole R. Evidence-based management of dyslipidaemia. Lancet 1995; 346: 1440-41.
15. Swales JD. The growth of medical science: the lessons of Malthus. The Harveian Oration of 1995. J R Coll Phys (London) 1995; 29: 490-501.
16. Ramsay LE. Mild hypertension: treat patients, not populations. J Hypertens 1985; 3: 449-55.
17. Cook RJ, Sackett DL. The number to treat: a clinically useful measure of treatment effect. Br Med J 1995; 310: 452-4.
18. Grover SA, Coupai L, Hu X-P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995; 274: 801-6.
19. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-8.
20. Pedersen TR. Lowering cholesterol with drugs and diet. N Engl J Med 1995; 333: 1350-1.
21. Mann JI, Crooke M, Fear H, et al on behalf of the Scientific Committee of the National Heart Foundation of New Zealand. Guidelines for detection and management of dyslipidaemia. NZ Med J 1993; 106: 132-42.
22. Bennett N, Dodd T, Flatley J, Freeth S, Boiling K for the Office of Population Censuses and Surveys. Health Survey for England 1993. London: HMSO, 1995.
23. Sever P, Beevers G, Bulpitt C et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. Br Med J 1993; 304: 983-7.
24. WHO-ISH Guidelines Subcommittee. Guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. J Hypertens 1993; 11: 905-18.
25. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med 1993; 153: 154-83.
26. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. Br Med J 1993; 307: 107-10.
27. Tyroler HA. Overview of clinical trials of cholesterol lowering in relationship to epidemiologic studies. Am J Med 1989; 17 (Suppl. 4A); 14-19S.
28. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465-77.
29. Imperial Cancer Research Fund OXCHECK Study Group. Effectiveness of health checks conducted by nurses in primary care: final results of the OXCHECK study. Br Med J 1995; 310: 1099-104.
30. Lindholm LH, Ekbom T, Dash C, Erisson M, Tibblin G, Schersten B. The impact of health care advice given in primary care on cardiovascular risk. Br Med J 1995; 310: 1105-9.
31. WHO Monica Project. Myocardial Infarction and coronary deaths in the World Health Organisation MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612.
32. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet 1982; 1: 185-91.
33. Davies G, Pyke S, Kinmonth A-L, on behalf of the Family Heart Study Group. Effect of non-attenders on the potential of a primary care programme to reduce cardiovascular risk in the population. Br Med J 1994; 309: 1553-6.
34. Rose G, Marmot MG. Social class and coronary disease. Br Heart J 1981; 45: 13-19.
35. Verschuren VMM, Jacobs DR, Bloemberg BPM et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty five year follow-up of the Seven Countries Study. JAMA 1995; 274: 131-6.
36. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. Br Med J 1991; 303: 953-7.
37. Yusuf S, Wittes J, Friedman L. Overview of results of randomised clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988; 260: 2259-63.
38. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994; 308: 367-72.
39. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L. Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. Br Med J 1995; 310: 975-8.
40. Evans J St B T, Harries C, Dennis I, Dean J. General practitioners' tacit and stated policies in the prescription of lipid lowering agents. Br J Gen Pract 1995; 45: 15-18.
41. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Interventions in OXCHECK study waste resources. Br Med J 1995; 311: 260.
42. Pickering TG. Treatment of mild hypertension and the reduction of cardiovascular mortality: the 'of or by' dilemma. JAMA 1983; 249: 399-400.